ETFOptimize | High-performance ETF-based Investment Strategies

Quantitative strategies, Wall Street-caliber research, and insightful market analysis since 1998.


ETFOptimize | HOME
Close Window

ICON recognised as leading contract research organisation and employer by Scrip, Fierce Life Sciences, Financial Times and others

ICON finishes the second half of 2022 with an impressive line-up of awards that commend its healthcare intelligence work and status as an employer of choice, as independently judged by industry leaders and peers worldwide.

ICON plc, (NASDAQ: ICLR) a world-leading healthcare intelligence and clinical research organisation, has been recognised with a number of coveted business and industry awards over the second half of 2022 for delivering clinical research services, alongside specialist collaborations on data, analytics and digital healthcare.

The awards include the Best Contract Research Organisation – Full-Service Providers from Scrip, marking the second consecutive time after a win in 2021. Winners are chosen by an independent panel of industry experts, each chosen for their knowledge, objectivity and credibility.

ICON’s innovation capabilities were recognised as the company won the Data Analytics/Business Intelligence category in the Fierce Biotech Innovation Awards – Life Sciences 2022. The award was for ICON’s proprietary One Search tool, which uses intuitive, integrated workflow and artificial intelligence to provide access to multiple data sources to help identify optimum trial sites the first time.

In November, ICON was recognised in the Financial Times European Leader in Diversity 2023 Award List, ranked 80th out of 850 companies. The list is based on independent surveys of more than 100,000 employees across the continent. They were given the chance to evaluate their own employer’s diversity and inclusion practices and to give their perception of those adopted by other prominent employers in their respective industries. This follows recognition earlier in the year from Forbes as one of America’s Best Employers for Diversity for the second year running.

Overall, ICON was named on the 2022 Forbes World’s Best Employers List, which is based on a survey of 150,000 full-time and part-time workers from 57 countries.

ICON CEO Steve Cutler commented on the wide range of awards: “We are pleased to be recognised across the board by industry groups and leaders as we continue our focus on healthcare intelligence. To be recognised for innovations that drive clinical research forward, build an inclusive and diverse workplace and for strong collaboration with our customers is testament to the tireless efforts of our talented employees around the globe.”

Additional industry awards and recognition

ICON also won a total of four gold awards at the 2022 MarCom Awards from the Association of Marketing and Communication Professionals. ICON’s Creative & Digital Services and Insight and Evidence & Value teams won a gold award in the Print Media/Marketing/Promotion/Materials category, while the Creative & Digital Services and Patient Recruitment Solutions teams won a gold award in the Digital Media/Web Video/Marketing category. Additionally, ICON’s Creative & Digital Services and Insights, Evidence & Value teams won two gold awards in the categories of Communications/Public Relations/Other – Health Equity-Multicultural and Marketing/Promotion Campaign/Branding Refresh.

Technology company Medidata awarded ICON a Collaboration of the Year award for contributions to its RAVE Imaging Platform. This accolade recognises a unique partnership aimed at delivering a flexible and high-quality imaging trial experience for sites, readers and sponsors.

In October, 33 ICON staff members won awards or were finalists in numerous categories at the PharmaTimes Clinical Researcher of the Year Americas Awards, including Experienced Contract Research Associate, Clinical Trial Manager, Global Project Manager, Start-up—Single, Start-up—Team, Global Project Team, and Global Partnership Team.

Further success for ICON in the closing months of 2022 came from wins in the Sales Promotion category and the Poster Design category at the 2022 Health + Wellness Design Awards hosted by Graphic Design USA, as well as the Established Irish Investor in Asia Award from Asia Matters.

A full list of ICON’s industry awards can be viewed at www.iconplc.com/awards.

About ICON plc

ICON is a world-leading healthcare intelligence and clinical research organisation. From molecule to medicine, we advance clinical research providing outsourced development and commercialisation services to pharmaceutical, biotechnology, medical device and government and public health organisations. We develop new innovations, drive emerging therapies forward and improve patient lives. With headquarters in Dublin, Ireland, ICON employed approximately 41,150 employees in 113 locations in 53 countries as at September 30, 2022. For further information about ICON, visit: www.iconplc.com.

ICON/ICLR-G

ICON finishes second half of 2022 with an impressive line-up of awards - recognised as leading contract research organisation and employer by Scrip, Fierce Life Sciences, Financial Times among others.

Contacts

Recent Quotes

View More
Symbol Price Change (%)
AMZN  229.25
+2.28 (1.00%)
AAPL  269.00
+0.19 (0.07%)
AMD  258.01
-1.66 (-0.64%)
BAC  52.87
-0.15 (-0.28%)
GOOG  268.43
-1.50 (-0.56%)
META  751.44
+0.62 (0.08%)
MSFT  542.07
+10.55 (1.98%)
NVDA  201.03
+9.54 (4.98%)
ORCL  280.83
-0.57 (-0.20%)
TSLA  460.55
+8.13 (1.80%)
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.


 

IntelligentValue Home
Close Window

DISCLAIMER

All content herein is issued solely for informational purposes and is not to be construed as an offer to sell or the solicitation of an offer to buy, nor should it be interpreted as a recommendation to buy, hold or sell (short or otherwise) any security.  All opinions, analyses, and information included herein are based on sources believed to be reliable, but no representation or warranty of any kind, expressed or implied, is made including but not limited to any representation or warranty concerning accuracy, completeness, correctness, timeliness or appropriateness. We undertake no obligation to update such opinions, analysis or information. You should independently verify all information contained on this website. Some information is based on analysis of past performance or hypothetical performance results, which have inherent limitations. We make no representation that any particular equity or strategy will or is likely to achieve profits or losses similar to those shown. Shareholders, employees, writers, contractors, and affiliates associated with ETFOptimize.com may have ownership positions in the securities that are mentioned. If you are not sure if ETFs, algorithmic investing, or a particular investment is right for you, you are urged to consult with a Registered Investment Advisor (RIA). Neither this website nor anyone associated with producing its content are Registered Investment Advisors, and no attempt is made herein to substitute for personalized, professional investment advice. Neither ETFOptimize.com, Global Alpha Investments, Inc., nor its employees, service providers, associates, or affiliates are responsible for any investment losses you may incur as a result of using the information provided herein. Remember that past investment returns may not be indicative of future returns.

Copyright © 1998-2017 ETFOptimize.com, a publication of Optimized Investments, Inc. All rights reserved.